Core Insights - Regeneron Pharmaceuticals is showcasing its hematology portfolio at the American Society of Hematology (ASH) 2025 Annual Meeting, with a focus on innovative treatments for blood cancers and disorders [2][3][11] - The company will present data on Lynozyfic™ (linvoseltamab-gcpt) and odronextamab, highlighting their potential as novel therapies in multiple myeloma and diffuse large B-cell lymphoma [3][4][15] Group 1: Lynozyfic™ (linvoseltamab-gcpt) - Lynozyfic is being evaluated in the Phase 1/2 LINKER-MM4 trial as a monotherapy for newly diagnosed multiple myeloma, marking the first trial of a BCMAxCD3 bispecific antibody in this context [3][15] - Additional results from the multicohort Phase 1b LINKER-MM2 trial will be shared, focusing on linvoseltamab combined with anti-CD38 monoclonal antibodies for relapsed/refractory multiple myeloma [3][6] Group 2: Odronextamab - Odronextamab will be featured in six abstracts, including its combination with chemotherapy for previously untreated diffuse large B-cell lymphoma, with initial results from the OLYMPIA-3 trial [4][19] - The program also includes results from two Phase 3 trials evaluating odronextamab in follicular lymphoma, both in combination with chemotherapy and lenalidomide [4][19] Group 3: Investor Engagement - Regeneron will host a virtual 'Regeneron Roundtable' investor event on December 10, 2025, to discuss its multiple myeloma development program [2][9] - This event is part of a series aimed at highlighting the company's innovative investigational pipeline [9][10] Group 4: Company Overview - Regeneron is recognized for its expertise in developing medicines for blood cancers and rare blood disorders, utilizing proprietary technologies like VelociSuite to create fully human antibodies [11][39] - The company is committed to addressing unmet medical needs in hematology through its extensive research and clinical development programs [11][12][39]